{"database": "lobbying", "table": "lobbying_activities", "rows": [[831870, "9a85cbf6-6738-45e5-9e11-452a51fbe7bd", "Q3", "AMYLIN PHARMACEUTICALS", 308536, "AMYLIN PHARMACEUTICALS", 2009, "third_quarter", "PHA", "Data exclusivity provisions in H.R. 1548, Pathway for Biosimilars Act\nData eclsuivity provisions in Promoting Innovation and Access to Life-Saving Medicine Act (H.R. 1427,S. 726)\nPhysician Payments Sunshine provision of H.R. 3200 America's Affordable Health Choices Act of 2009\nFDA Risk Evaulation Mitigation Strategies (REMS) Drug Safety Communications\nDrug importation issues", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", null, 330000, 0, 0, "2009-10-16T12:45:25-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["831870"], "units": {}, "query_ms": 188.6317899916321, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}